Polbionica S.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2025-01-21
Share capital
607,024.00 PLN
Activity description

Polbionica is a leader in 3D bioprinting, developing the world's first functional bionic pancreas made from living cells that can produce insulin and glucagon. The company provides proprietary bioprinting materials, such as TintBionic® and Printiss®, and operates the ResearchLine™ bioreactor for tissue and organ cultivation. Their innovations aim to revolutionize the treatment of chronic diseases, particularly diabetes.

Registered address
ul. Nowy Kisielin-A. Wysockiego 1, 66-002 Zielona Góra, Poland
Electronic delivery address
AE:PL-76541-34063-STFWG-13

Financials

Revenue history (in k)

From the notes

Current income tax (CIT due)$0

Filing timeliness

Financial statements were filed on time, on average 7 days early. All were audited by a statutory auditor.

  • 202507/07/2026
  • 202410/07/2025
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 34%
Top 32%
City · Zielona Góra689 / 1,612
Top 43%
Voivodeship · Lubuskie2,630 / 5,363
Top 49%
Country · Poland139,002 / 297,566
Top 47%

Results vs industry

Revenue
This companyUSD 356.01kMedianUSD 153.26kAverageUSD 4.77m
Net profit
This companyUSD -1.25mMedianUSD -293.45AverageUSD 307.82k
Operating costs
This companyUSD 1.56mMedianUSD 188.47kAverageUSD 4.59m
Assets
This companyUSD 8.62mMedianUSD 281.58kAverageUSD 8.35m

Website technology

Online shop
  • WooCommerce
Website
  • WordPress

Public procurement

The company is the contractor in 2 public sector contracts, worth USD 1.20k in total. They were signed with 2 public buyers.

SubjectAmount
Purchase – UV lamp
$636.68
Chemical reagents for highly specialized research applications
$566.99

Authorized Representatives

Tomasz Bąkowski age 43 – Management Board Member
Filip Fertner age 51 – Vice President of the Management Board
Marta Klak age 39 – Vice President of the Management Board
Michał Wszoła age 52 – President of the Management Board

Manner of representation

In the case of a management board consisting of two or more persons, joint action by two members of the management board is required to make declarations of will on behalf of the company.

Supervisory board

Agnieszka Dobrzyń age 53 – Supervisory Board Member
Paweł Dziekoński age 47 – Supervisory Board Member
Monika Godlewska age 37 – Supervisory Board Member
Wojciech Święszkowski age 56 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2020-06-01.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Buildings and premises
PLN 17,554

MSiG notices

Publication dateEvent
Jan 31, 2025Transformation registered

Public aid

8 public aid cases recorded, with a total value of $4,229,621.

PurposeGross amount
Aid for research and development projects: industrial research
–
Aid for research and development projects: experimental development
–
Aid for projects awarded a Seal of Excellence quality label
–

European Funds

ProjectEU co-financing
3D bioprinted bionic pancreas as a therapy for type 1 diabetes
$2.6M
3D bioprinted liver tissue with a vascular system as an innovative model for evaluating drug toxicity and the effectiveness of anticancer therapies
$2.3M
Preparation of an application to the Horizon 2020-Accelerator programme to develop a unique technology for 3D printing a bionic pancreas.
$15,129

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Human Biome S.A.
Piero Composites sp. z o.o.
Medicofarma Biotech S.A.
SKIN Lab International sp. z o.o.
Albi-Tech sp. z o.o.
F1 Pharma S.A.
Phage Consultants sp. z o.o.
123d sp. z o.o.
Eduroco sp. z o.o.
Awtm sp. z o.o.

Change history

DateEvent
2025-10-08Share capital increase
2025-08-13Address change
2025-01-21Entered in the register

FAQ

Last updated: 2026-09-08